Metastatic Melanoma - Pipeline Review, H2 2016

Lowest Prices Guaranteed	Length	Publisher	Published Date	SKU
from $2,000	648 Pages	Global Markets Direct	September, 2016	GMD15165616

Lowest Prices Guaranteed
Price	from $2,000
Length	648 Pages
Publisher	Global Markets Direct
Published Date	September, 2016
SKU	GMD15165616

Single User License:	$2,000
Site License:	$4,000
Global Site License:	$6,000

Research assistance

US: 800.298.5699

Int'l: +1.240.747.3093

Table of Contents
Description

Metastatic Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Melanoma - Pipeline Review, H2 2016’, provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Introduction: Metastatic Melanoma Overview; Therapeutics Development; Metastatic Melanoma - Therapeutics under Development by Companies; Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes; Metastatic Melanoma - Pipeline Products Glance; Metastatic Melanoma - Products under Development by Companies; Metastatic Melanoma - Products under Investigation by Universities/Institutes; Metastatic Melanoma - Companies Involved in Therapeutics Development; Metastatic Melanoma - Therapeutics Assessment; Drug Profiles; Metastatic Melanoma - Dormant Projects; Metastatic Melanoma - Discontinued Products; Metastatic Melanoma - Product Development Milestones
Appendix
List of Tables: Number of Products under Development for Metastatic Melanoma, H2 2016; Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016; Number of Products under Development by Companies, H2 2016; Number of Products under Development by Companies, H2 2016 (Contd..1); Number of Products under Development by Companies, H2 2016 (Contd..2); Number of Products under Development by Companies, H2 2016 (Contd..3); Number of Products under Development by Companies, H2 2016 (Contd..4); Number of Products under Development by Companies, H2 2016 (Contd..5); Number of Products under Investigation by Universities/Institutes, H2 2016; Comparative Analysis by Late Stage Development, H2 2016; Comparative Analysis by Clinical Stage Development, H2 2016; Comparative Analysis by Early Stage Development, H2 2016; Products under Development by Companies, H2 2016; Products under Development by Companies, H2 2016 (Contd..1); Products under Development by Companies, H2 2016 (Contd..2); Products under Development by Companies, H2 2016 (Contd..3); Products under Development by Companies, H2 2016 (Contd..4); Products under Development by Companies, H2 2016 (Contd..5); Products under Development by Companies, H2 2016 (Contd..6); Products under Development by Companies, H2 2016 (Contd..7); Products under Investigation by Universities/Institutes, H2 2016; Metastatic Melanoma - Pipeline by AB Science SA, H2 2016; Metastatic Melanoma - Pipeline by AbbVie Inc, H2 2016; Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016; Metastatic Melanoma - Pipeline by Affichem SA, H2 2016; Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2016; Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H2 2016; Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H2 2016; Metastatic Melanoma - Pipeline by Amgen Inc., H2 2016; Metastatic Melanoma - Pipeline by Angimmune LLC, H2 2016; Metastatic Melanoma - Pipeline by Apexigen, Inc., H2 2016; Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by Array BioPharma Inc., H2 2016; Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by AstraZeneca Plc, H2 2016; Metastatic Melanoma - Pipeline by Basilea Pharmaceutica Ltd., H2 2016; Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by BerGenBio AS, H2 2016; Metastatic Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016; Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2016; Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016; Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016; Metastatic Melanoma - Pipeline by Calithera Biosciences, Inc., H2 2016; Metastatic Melanoma - Pipeline by Cellceutix Corporation, H2 2016; Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016; Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H2 2016; Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2016; Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2016; Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H2 2016; Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2016; Metastatic Melanoma - Pipeline by Eli Lilly and Company, H2 2016; Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H2 2016; Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016; Metastatic Melanoma - Pipeline by Galapagos NV, H2 2016; Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2016; Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016; Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by Ignyta, Inc., H2 2016; Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2016; Metastatic Melanoma - Pipeline by Immunocore Limited, H2 2016; Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2016; Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2016; Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by IO Biotech ApS, H2 2016; Metastatic Melanoma - Pipeline by Lentigen Technology, Inc., H2 2016; Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2016; Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2016; Metastatic Melanoma - Pipeline by MacroGenics, Inc., H2 2016; Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2016; Metastatic Melanoma - Pipeline by Medivation, Inc., H2 2016; Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H2 2016; Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2016; Metastatic Melanoma - Pipeline by Merck KGaA, H2 2016; Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016; Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H2 2016; Metastatic Melanoma - Pipeline by Moleculin Biotech Inc, H2 2016; Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2016; Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H2 2016; Metastatic Melanoma - Pipeline by Novartis AG, H2 2016; Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2016; Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2016; Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H2 2016; Metastatic Melanoma - Pipeline by Onxeo SA, H2 2016; Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2016; Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H2 2016; Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2016; Metastatic Melanoma - Pipeline by PinCell srl, H2 2016; Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2016; Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H2 2016; Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H2 2016; Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H2 2016; Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H2 2016; Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2016; Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2016; Metastatic Melanoma - Pipeline by Sillajen Biotherapeutics, H2 2016; Metastatic Melanoma - Pipeline by SolaranRx, Inc., H2 2016; Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016; Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2016; Metastatic Melanoma - Pipeline by TC BioPharm Limited, H2 2016; Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H2 2016; Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2016; Assessment by Monotherapy Products, H2 2016; Assessment by Combination Products, H2 2016; Number of Products by Stage and Target, H2 2016; Number of Products by Stage and Mechanism of Action, H2 2016; Number of Products by Stage and Route of Administration, H2 2016; Number of Products by Stage and Molecule Type, H2 2016; Metastatic Melanoma - Dormant Projects, H2 2016; Metastatic Melanoma - Dormant Projects (Contd..1), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..2), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..3), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..4), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..5), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..6), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..7), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..8), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..9), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..10), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..11), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..12), H2 2016; Metastatic Melanoma - Dormant Projects (Contd..13), H2 2016; Metastatic Melanoma - Discontinued Products, H2 2016; Metastatic Melanoma - Discontinued Products (Contd..1), H2 2016
List of Figures: Number of Products under Development for Metastatic Melanoma, H2 2016; Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2016; Number of Products under Development by Companies, H2 2016; Number of Products under Investigation by Universities/Institutes, H2 2016; Comparative Analysis by Late Stage Development, H2 2016; Comparative Analysis by Clinical Stage Development, H2 2016; Comparative Analysis by Early Stage Products, H2 2016; Assessment by Monotherapy Products, H2 2016; Assessment by Combination Products, H2 2016; Number of Products by Top 10 Targets, H2 2016; Number of Products by Stage and Top 10 Targets, H2 2016; Number of Products by Top 10 Mechanism of Actions, H2 2016; Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016; Number of Products by Top 10 Routes of Administration, H2 2016; Number of Products by Stage and Top 10 Routes of Administration, H2 2016; Number of Products by Top 10 Molecule Types, H2 2016; Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Metastatic Melanoma - Pipeline Review, H2 2016

Tasks